ATE429247T1 - Hla-bindende peptide und ihre verwendungen - Google Patents

Hla-bindende peptide und ihre verwendungen

Info

Publication number
ATE429247T1
ATE429247T1 AT99928792T AT99928792T ATE429247T1 AT E429247 T1 ATE429247 T1 AT E429247T1 AT 99928792 T AT99928792 T AT 99928792T AT 99928792 T AT99928792 T AT 99928792T AT E429247 T1 ATE429247 T1 AT E429247T1
Authority
AT
Austria
Prior art keywords
hla
peptides
binding peptides
immunogenic
allele
Prior art date
Application number
AT99928792T
Other languages
English (en)
Inventor
Alessandro Sette
John Sidney
Scott Southwood
Original Assignee
Idm Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idm Pharma Inc filed Critical Idm Pharma Inc
Application granted granted Critical
Publication of ATE429247T1 publication Critical patent/ATE429247T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99928792T 1998-06-17 1999-06-17 Hla-bindende peptide und ihre verwendungen ATE429247T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9858498A 1998-06-17 1998-06-17
PCT/US1999/013789 WO1999065522A1 (en) 1998-06-17 1999-06-17 Hla binding peptides and their uses

Publications (1)

Publication Number Publication Date
ATE429247T1 true ATE429247T1 (de) 2009-05-15

Family

ID=22269985

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99928792T ATE429247T1 (de) 1998-06-17 1999-06-17 Hla-bindende peptide und ihre verwendungen

Country Status (8)

Country Link
EP (2) EP1089757B1 (de)
JP (2) JP2002518346A (de)
AT (1) ATE429247T1 (de)
AU (1) AU4577899A (de)
CA (1) CA2330824A1 (de)
DE (1) DE69940774D1 (de)
ES (1) ES2326146T3 (de)
WO (1) WO1999065522A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
DE19925199A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925235A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
GB9923309D0 (en) * 1999-10-01 1999-12-08 Glaxo Group Ltd Assay
WO2001041788A1 (en) * 1999-12-10 2001-06-14 Epimmune, Inc. INDUCING CELLULAR IMMUNE RESPONSES TO p53 USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
EP1766393A4 (de) * 2004-05-07 2008-06-18 Beckman Coulter Inc Mhc-brückensystem zum nachweis der ctl-vermittelten lyse antigenpräsentierender zellen
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
KR20160037196A (ko) 2013-07-31 2016-04-05 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 종양 연관된 탄수화물 항원을 표적으로 하는 암을 치료하고 예방하기 위한 조성물과 방법

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4844893A (en) 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0452457B1 (de) 1989-11-03 1997-08-20 Vanderbilt University Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US5972351A (en) * 1992-04-03 1999-10-26 Isis Innovation Limited Plasmodium falciparum MHC class I-restricted CTL epitopes derived from pre-erythrocytic stage antigens
ES2139012T3 (es) * 1992-05-26 2000-02-01 Univ Leiden Peptidos de la proteina p53 humana destinados para ser utilizados en composiciones que inducen una reaccion en los linfocitos t humanos, y linfocitos t citotoxicos especificos de la proteina p53 humana.
WO1993024640A2 (en) 1992-06-04 1993-12-09 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
SG52492A1 (en) * 1992-08-07 1998-09-28 Cytel Corp Hla binding peptides and their uses
JP3908271B2 (ja) * 1993-03-05 2007-04-25 エピミューン，インコーポレイティド Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用
JP3926839B2 (ja) 1993-09-14 2007-06-06 エピミューン，インコーポレイティド 万能ｄｒ−結合性ペプチドを用いる免疫応答の改変
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
EP0793501A4 (de) * 1994-12-14 2000-05-03 Scripps Research Inst 'in vivo'aktivierung von tumorspezifischen-zytotoxischen t-zellen
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
JP4108126B2 (ja) * 1996-04-26 2008-06-25 リュクスウニヴェルシテート テ レイデン Ｔ細胞ペプチド・エピトープの選択と産生方法および選択したエピトープを組込むワクチン

Also Published As

Publication number Publication date
EP1089757B1 (de) 2009-04-22
ES2326146T3 (es) 2009-10-01
DE69940774D1 (de) 2009-06-04
EP2036573A1 (de) 2009-03-18
EP1089757A1 (de) 2001-04-11
WO1999065522A1 (en) 1999-12-23
EP1089757A4 (de) 2002-10-30
AU4577899A (en) 2000-01-05
JP2010090167A (ja) 2010-04-22
JP2002518346A (ja) 2002-06-25
CA2330824A1 (en) 1999-12-23

Similar Documents

Publication Publication Date Title
ATE512666T1 (de) Hla-bindende peptide und ihre verwendungen
ATE536187T1 (de) Hla-klasse-i- und -klasse-ii-bindende peptide und ihre verwendungen
BR9406652A (pt) Composição
DE69334076D1 (de) Hla bindepeptide und ihre verwendungen
DE69733352D1 (de) Hla-a2.1 bindende peptide und deren verwendung
DK0941478T3 (da) Assaymetode for peptidspecifikke T-celler
DE60142689D1 (de) Verwendung prokariotischer pest-ähnlicher peptide zur verstärkung der immunogenität von antigenen
CY1108083T1 (el) Αντιγονα και συνθεσεις του neisseria meningitidis
ATE329617T1 (de) Antigen enthaltende zusammensetzung, die zusätzlich derivatisierte monoglyceride oder diglyceride als adjuvantien enthält
AU5963500A (en) Peptides for vaccinating against human cmv
DK0643726T3 (da) Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei
DE69940774D1 (de) Hla-bindende peptide und ihre verwendungen
WO2004007528A3 (en) Novel compositions and methods for the generation of mhc class ii compounds by peptide exchange
ATE502952T1 (de) Hla-bindungspeptide und ihre anwendungszwecke
DK1230261T3 (da) NY-ESO-1 Nonapeptidderivater og anvendelser af disse
WO1999009167A8 (en) Porcine mhc class i genes and uses thereof
WO2004011483A3 (en) Isolated, ssx-2 and ssx-2 related peptides useful as hla binders and ctl epitopes, and uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties